ArticleThoracic cancer2026

The Efficacy and Safety of Nab-Paclitaxel Plus Anlotinib in Small-Cell Lung Cancer for Second-Line Therapy.

Li-Jun Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.